Prolyl Endopeptidase
Celiac Disease
Dr. C. Bonorino Udaondo Gastroenterology Hospitalprotein_peptidePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
16 Active assets in the Celiac Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Necator Americanus James Cook University, Queensland, Australia | Phase 2 | BB |
MACROGOLS Sheffield Teaching Hospitals NHS Foundation Trust | Phase 4 | BB |
Latiglutenase Entero Therapeutics | Phase 2 | BB |
Larazotide 9 Meters Biopharma, Inc. | Phase 3 | BB |
SIMVASTATIN Entero Therapeutics | Phase 2/3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →